文献速递膀胱癌与上尿路尿路上皮癌

帕博利珠单抗联合放化疗治疗肌层浸润性膀胱癌:PCR-MIB 2期临床试验(ANZUP 1502)的安全性与有效性分析

Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
PubMed 文献 · Eur Urol Oncol · 2023-10-07

这项单臂2期试验纳入28例cT2-T4aN0M0肌层浸润性膀胱癌患者,评估帕博利珠单抗联合放化疗的可行性与安全性。主要终点为可行性,24周完全缓解率为88%,2年无远处转移生存率78%,中位总生存39个月。联合方案可行、毒性可控,完全缓解率令人鼓舞。

要点

  • 28例肌层浸润性膀胱癌患者接受帕博利珠单抗联合放化疗,中位随访31个月。
  • 6例出现3级以上非泌尿系统不良事件,3例需多次降低顺铂剂量。
  • 24周完全缓解率88%,2年无远处转移生存率78%,中位总生存39个月。

核心结论

  • 帕博利珠单抗联合放化疗治疗肌层浸润性膀胱癌可行,毒性可控,完全缓解率令人鼓舞。
  • 需进一步开展更大规模的试验。

研究设计与样本

  • 单臂2期临床试验(ANZUP 1502)。
  • 纳入28例cT2-T4aN0M0肌层浸润性膀胱癌患者,美国东部肿瘤协作组体能状态0-1分,估算肾小球滤过率≥40 ml/min,无帕博利珠单抗禁忌证,适合放化疗。

主要发现

  • 中位随访31个月,6例在治疗期间或治疗后12周内出现3级以上非泌尿系统不良事件,3例顺铂剂量降低超过一次。
  • 放化疗后24周完全缓解率为88%。
  • 8例发生转移性疾病,3例出现非转移性进展。
  • 2年无远处转移生存率为78%(95%CI 54-90%),2年局部区域无进展生存率为87%(95%CI 64-96%),中位总生存期为39个月(95%CI 17.1-不可评估)。

关键数值与推荐

  • 主要终点可行性由预先规定的3级或以上非泌尿系统毒性低满意率或按既定参数完成计划放化疗判定。
  • 放疗方案:全膀胱放疗64 Gy分32次,每日一次,持续6.5周。
  • 顺铂35 mg/m2静脉注射每周一次,共六剂;帕博利珠单抗200 mg静脉注射每3周一次,共七剂,均从放疗开始时给药。
  • 放化疗后12周和24周进行监测性膀胱镜检查/活检和计算机断层扫描。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性为单臂设计和样本量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation may improve the efficacy of immune checkpoint inhibition. This study investigates the combination of pembrolizumab and chemoradiation (CRT) for muscle-invasive bladder cancer (MIBC). OBJECTIVE: To assess the feasibility and safety of pembrolizumab combined with CRT for MIBC. DESIGN, SETTING, AND PARTICIPANTS: A single-arm phase 2 trial was performed with 28 participants having cT2-T4aN0M0 MIBC (Eastern Cooperative Oncology Group performance status 0-1; estimated glomerular filtration rate ≥40 ml/min; no contraindications to pembrolizumab) suitable for CRT. INTERVENTION: Whole bladder radiation therapy (RT; 64 Gy in 32 daily fractions, over 6.5 wk, combined with cisplatin (35 mg/m2 intravenously [IV] weekly, six doses) and pembrolizumab (200 mg IV q3 weeks, seven doses), both starting with RT. Surveillance cystoscopy/biopsy and computerised tomography scans performed 12 and 24 wk after CRT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was feasibility, determined by a prespecified satisfactory low rate of grade 3 or worse nonurinary toxicity or completion of planned CRT according to defined parameters. Secondary endpoints were complete cystoscopic response, locoregional progression-free survival (LRPFS), distant metastasis-free survival (DMFS), and overall survival (OS). RESULTS AND LIMITATIONS: Twenty-eight patients were enrolled with a 31-mo median follow-up. Six had Grade >3 nonurinary adverse events during/within 12 wk after treatment; three had more than one cisplatin dose reduction. The 24-wk post-CRT complete response (CR) rate was 88%. Eight patients developed metastatic disease, and three had nonmetastatic progression. The DMFS at 2 yr is 78% (95% confidence interval [CI] 54-90%), with LRPFS at 2 yr of 87% (95% CI 64-96%) and median OS of 39 mo (95% CI 17.1-not evaluable). Limitations are the single-arm design and sample size. CONCLUSIONS: Combining pembrolizumab with CRT for MIBC was feasible, with manageable toxicity and promising CR rates. PATIENT SUMMARY: Immunotherapy treats nonmetastatic/metastatic bladder cancer effectively. We combined pembrolizumab with chemotherapy and radiation to assess its safety and impact on treatment delivery. The combination was feasible with encouraging early activity. Further larger trials are warranted.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Weickhardt A, Foroudi F, Lawrentschuk N, et al. Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502). Eur Urol Oncol. 2023. PMID: 37806844. doi:10.1016/j.euo.2023.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。